{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:48:27Z","timestamp":1772012907412,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute of Drug Abuse","doi-asserted-by":"crossref","award":["R25-DA13582"],"award-info":[{"award-number":["R25-DA13582"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute of Drug Abuse","doi-asserted-by":"crossref","award":["R01DA031059"],"award-info":[{"award-number":["R01DA031059"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute of Drug Abuse","doi-asserted-by":"crossref","award":["K23DA027367"],"award-info":[{"award-number":["K23DA027367"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jsat.2016.01.009","type":"journal-article","created":{"date-parts":[[2016,2,14]],"date-time":"2016-02-14T03:41:03Z","timestamp":1455421263000},"page":"54-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders"],"prefix":"10.1016","volume":"66","author":[{"given":"Katelyn J.","family":"Carey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin P.","family":"Linas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith I.","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.jsat.2016.01.009_bb0010","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/cid\/cit305","article-title":"Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study","volume":"57","author":"Alavi","year":"2013","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2016.01.009_bb0015","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","article-title":"Five year experience with collaborative care of opioid addicted patients using buprenorphine in primary care","volume":"171","author":"Alford","year":"2011","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.jsat.2016.01.009_bb0020","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1086\/588297","article-title":"Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994\u20132004","volume":"46","author":"Amon","year":"2008","journal-title":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.jsat.2016.01.009_bb0025","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jsat.2016.01.009_bb0030","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1353\/hpu.2014.0093","article-title":"Quality of hepatitis C care at an urban tertiary care medical center","volume":"25","author":"Assoumou","year":"2014","journal-title":"Journal of Health Care for the Poor and Underserved"},{"key":"10.1016\/j.jsat.2016.01.009_bb0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jsat.2016.01.009_bb0040","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/jvh.12008","article-title":"Accessing hepatitis C patients who are difficult to reach: It is time to overcome barriers","volume":"19","author":"Bruggmann","year":"2012","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.jsat.2016.01.009_bb0045","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/gut.2006.099150","article-title":"Rate and predictors of treatment prescription for hepatitis C","volume":"56","author":"Butt","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jsat.2016.01.009_bb0050","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1360-0443.1997.tb02979.x","article-title":"Methadone maintenance and hepatitis C virus infection among injecting drug users","volume":"92","author":"Crofts","year":"1997","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.jsat.2016.01.009_bb0055","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/cid\/cis1007","article-title":"Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis","volume":"56","author":"Dimova","year":"2013","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2016.01.009_bb0060","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jhep.2013.11.014","article-title":"The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010","volume":"60","author":"Ditah","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.jsat.2016.01.009_bb0065","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1007\/s10461-011-0054-4","article-title":"Change in HIV\u2014HCV risk-taking behavior and seroprevalence among opiate users seeking treatment over an 11-year period and harm reduction policy","volume":"16","author":"Fatseas","year":"2012","journal-title":"AIDS and Behavior"},{"key":"10.1016\/j.jsat.2016.01.009_bb0070","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/08897077.2013.819828","article-title":"A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment","volume":"35","author":"Fingerhood","year":"2014","journal-title":"Substance Abuse: Official Publication of the Association for Medical Education and Research in Substance Abuse"},{"key":"10.1016\/j.jsat.2016.01.009_bb0075","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: An update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.jsat.2016.01.009_bb0080","author":"Greene"},{"key":"10.1016\/j.jsat.2016.01.009_bb0085","first-page":"285","article-title":"Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system","volume":"22","author":"Gryczynski","year":"2013","journal-title":"The American Journal on Addictions\/American Academy of Psychiatrists in Alcoholism and Addictions"},{"key":"10.1016\/j.jsat.2016.01.009_bb0090","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.drugalcdep.2006.09.018","article-title":"Referral for chronic hepatitis C treatment from a drug dependency treatment setting","volume":"88","author":"Hallinan","year":"2007","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2016.01.009_bb0095","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1086\/600304","article-title":"Hepatitis C treatment for injection drug users: A review of the available evidence","volume":"49","author":"Hellard","year":"2009","journal-title":"Clinical infectious diseases: An official publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.jsat.2016.01.009_bb0100","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","volume":"62","author":"Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus","year":"2015","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.jsat.2016.01.009_bb0105","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1046\/j.1360-0443.2002.00208.x","article-title":"The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users","volume":"97","author":"Kwiatkowski","year":"2002","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2016.01.009_bb0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jsat.2008.09.009","article-title":"Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program","volume":"37","author":"Litwin","year":"2009","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2016.01.009_bb0005","author":"Medicaid Coverage and Financing of Medications to Treat Alcohol and Opioid Use Disorders|SAMHSA"},{"key":"10.1016\/j.jsat.2016.01.009_bb0115","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users","volume":"33","author":"Mehta","year":"2008","journal-title":"Journal of Community Health"},{"key":"10.1016\/j.jsat.2016.01.009_bb0120","series-title":"AIDS October 2005","article-title":"A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV\/HCV-co-infected injection drug users","author":"Mehta","year":"2005"},{"key":"10.1016\/j.jsat.2016.01.009_bb0125","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11606-007-0129-0","article-title":"Primary care office-based buprenorphine treatment: Comparison of heroin and prescription opioid dependent patients","volume":"22","author":"Moore","year":"2007","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.jsat.2016.01.009_bb0130","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jsat.2016.01.009_bb0135","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1360-0443.2008.02188.x","article-title":"Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients","volume":"103","author":"Novick","year":"2008","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.jsat.2016.01.009_bb0140","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/ADM.0b013e31820e13dd","article-title":"Low risk for hepatitis C seroconversion in methadone maintenance treatment","volume":"5","author":"Peles","year":"2011","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2016.01.009_bb0145","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drugalcdep.2012.06.020","article-title":"Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine\/naloxone treatment","volume":"127","author":"Savant","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2016.01.009_bb0150","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1360-0443.2009.02509.x","article-title":"Psychopathological changes and quality of life in hepatitis C virus-infected, opioid-dependent patients during maintenance therapy","volume":"104","author":"Sch\u00e4fer","year":"2009","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.jsat.2016.01.009_bb0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drugalcdep.2004.07.002","article-title":"The impact of injecting drug use status on hepatitis C-related referral and treatment","volume":"77","author":"Stoov\u00e9","year":"2005","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2016.01.009_bb0160","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.jsat.2016.01.009_bb0165","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/hep.23220","article-title":"Public health impact of antiviral therapy for hepatitis C in the United States","volume":"50","author":"Volk","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.jsat.2016.01.009_bb0170","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1093\/cid\/cis392","article-title":"Hepatitis C virus prevention, care, and treatment: From policy to practice","volume":"55","author":"Ward","year":"2012","journal-title":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.jsat.2016.01.009_bb0175","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000000041","article-title":"Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance","author":"Zeremski","year":"2014","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2016.01.009_bb0180","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/ADM.0b013e31825f491b","article-title":"Perceived barriers to hepatitis C therapy for patients receiving opioid agonist treatment","volume":"6","author":"Zickmund","year":"2012","journal-title":"Journal of Addiction Medicine"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547216000416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547216000416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:44:33Z","timestamp":1760039073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547216000416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":36,"alternative-id":["S0740547216000416"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2016.01.009","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2016.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}